Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study

Virological response to peginterferon + ribavirin (P+R) at week 4 can predict sustained virological response (SVR). While patients with rapid virological response (RVR) do not require triple therapy, patients with a decline

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2015-03, Vol.10 (3), p.e0122613-e0122613
Hauptverfasser:	Romero-Gómez, Manuel, Turnes, Juan, Ampuero, Javier, Oyagüez, Itziar, Cuenca, Beatriz, Gonzalez-Garcia, Juan, Muñoz-Molina, Belén, Aguilar, Rocio, Leal, Sandra, Planas, Ramon, Garcia-Samaniego, Javier, Diago, Moises, Crespo, Javier, Calleja, Jose Luis, Casado, Miguel Angel, Sola, Ricard
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Analysis Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use Care and treatment Clinical medicine Cost analysis Decision making Diagnostic systems Female Fibrosis Gene polymorphism Genetic polymorphisms Genotype & phenotype Genotypes Hepatitis Hepatitis C Hepatitis C - drug therapy Hepatitis C - virology Hepatitis C virus Hepatology HIV Hospitals Human immunodeficiency virus Humans Infections Interferon Interferon-alpha - administration & dosage Interferon-alpha - chemistry Male Mathematical models Middle Aged Patients Pharmacoeconomics Polyethylene Glycols - chemistry Polymorphism Prospective Studies Ribavirin Ribavirin - administration & dosage Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Virological response to peginterferon + ribavirin (P+R) at week 4 can predict sustained virological response (SVR). While patients with rapid virological response (RVR) do not require triple therapy, patients with a decline
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0122613